These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22166793)

  • 41. Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease.
    Averbeck BB; Djamshidian A; O'Sullivan SS; Housden CR; Roiser JP; Lees AJ
    Behav Neurosci; 2013 Apr; 127(2):245-55. PubMed ID: 23565936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine-Dependent Loss Aversion during Effort-Based Decision-Making.
    Chen X; Voets S; Jenkinson N; Galea JM
    J Neurosci; 2020 Jan; 40(3):661-670. PubMed ID: 31727795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychophysiological evidence for impaired reward anticipation in Parkinson's disease.
    Mattox ST; Valle-Inclán F; Hackley SA
    Clin Neurophysiol; 2006 Oct; 117(10):2144-53. PubMed ID: 16920018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Learning to be inflexible: Enhanced attentional biases in Parkinson's disease.
    Fallon SJ; Hampshire A; Barker RA; Owen AM
    Cortex; 2016 Sep; 82():24-34. PubMed ID: 27318659
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors.
    Housden CR; O'Sullivan SS; Joyce EM; Lees AJ; Roiser JP
    Neuropsychopharmacology; 2010 Oct; 35(11):2155-64. PubMed ID: 20631686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Personality, addiction, dopamine: insights from Parkinson's disease.
    Dagher A; Robbins TW
    Neuron; 2009 Feb; 61(4):502-10. PubMed ID: 19249271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopaminergic medication increases motivation to exert cognitive control by reducing subjective effort costs in Parkinson's patients.
    Bogdanov M; LoParco S; Otto AR; Sharp M
    Neurobiol Learn Mem; 2022 Sep; 193():107652. PubMed ID: 35724812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploring reward-related attention selectivity deficits in Parkinson's disease.
    Pilgrim MJD; Ou ZA; Sharp M
    Sci Rep; 2021 Sep; 11(1):18751. PubMed ID: 34548517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine promotes instrumental motivation, but reduces reward-related vigour.
    Grogan JP; Sandhu TR; Hu MT; Manohar SG
    Elife; 2020 Oct; 9():. PubMed ID: 33001026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An EEG marker of reward processing is diminished in Parkinson's disease.
    Brown DR; Richardson SP; Cavanagh JF
    Brain Res; 2020 Jan; 1727():146541. PubMed ID: 31704082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The interactive effect of valence and context on reversal learning in individuals with Parkinson's disease.
    Levy-Gigi E; Haim-Nachum S; Hall JM; Crouse JJ; Winwood-Smith R; Lewis SJG; Moustafa AA
    Neurosci Lett; 2019 Jan; 692():216-224. PubMed ID: 30412753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association Between a Variable Number Tandem Repeat Polymorphism Within the DAT1 Gene and the Mesolimbic Pathway in Parkinson's Disease.
    du Plessis S; Bekker M; Buckle C; Vink M; Seedat S; Bardien S; Carr J; Abrahams S
    Front Neurol; 2020; 11():982. PubMed ID: 32982958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopaminergic Therapy Increases Go Timeouts in the Go/No-Go Task in Patients with Parkinson's Disease.
    Yang XQ; Lauzon B; Seergobin KN; MacDonald PA
    Front Hum Neurosci; 2017; 11():642. PubMed ID: 29354045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine-related personality traits in Parkinson's disease.
    Menza MA; Golbe LI; Cody RA; Forman NE
    Neurology; 1993 Mar; 43(3 Pt 1):505-8. PubMed ID: 8450991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impulsive behavior and associated clinical variables in Parkinson's disease.
    Abosch A; Gupte A; Eberly LE; Tuite PJ; Nance M; Grant JE
    Psychosomatics; 2011; 52(1):41-7. PubMed ID: 21300194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cognitive slowing in Parkinson's disease: a behavioral evaluation independent of motor slowing.
    Sawamoto N; Honda M; Hanakawa T; Fukuyama H; Shibasaki H
    J Neurosci; 2002 Jun; 22(12):5198-203. PubMed ID: 12077214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of Motor Vigor by Expectation of Reward Probability Trial-by-Trial Is Preserved in Healthy Ageing and Parkinson's Disease Patients.
    Tecilla M; Großbach M; Gentile G; Holland P; Sporn S; Antonini A; Herrojo Ruiz M
    J Neurosci; 2023 Mar; 43(10):1757-1777. PubMed ID: 36732072
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms Underlying Dopamine-Induced Risky Choice in Parkinson's Disease With and Without Depression (History).
    Timmer MHM; Sescousse G; Esselink RAJ; Piray P; Cools R
    Comput Psychiatr; 2018 Feb; 2():11-27. PubMed ID: 30090860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Do Patients With Parkinson's Disease Exhibit Reduced Cheating Behavior? A Neuropsychological Study.
    Abe N; Kawasaki I; Hosokawa H; Baba T; Takeda A
    Front Neurol; 2018; 9():378. PubMed ID: 29881370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How schizophrenia and depression disrupt reward circuitry.
    Holcomb HH; Rowland LM
    Curr Treat Options Neurol; 2007 Sep; 9(5):357-62. PubMed ID: 17716599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.